Soluble Ferric Pyrophosphate (SFP)
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Renal Failure Chronic Requiring Hemodialysis
Conditions
Renal Failure Chronic Requiring Hemodialysis
Trial Timeline
Apr 1, 2011 → Feb 1, 2014
NCT ID
NCT01322347About Soluble Ferric Pyrophosphate (SFP)
Soluble Ferric Pyrophosphate (SFP) is a phase 3 stage product being developed by Rockwell Medical for Renal Failure Chronic Requiring Hemodialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT01322347. Target conditions include Renal Failure Chronic Requiring Hemodialysis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01322347 | Phase 3 | Completed |
| NCT01320202 | Phase 3 | Completed |
| NCT00604565 | Pre-clinical | Terminated |
Competing Products
20 competing products in Renal Failure Chronic Requiring Hemodialysis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109 | MBX Biosciences | Phase 1 | 28 |
| LY3473329 | Eli Lilly | Phase 1 | 33 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont | Spruce Biosciences | Phase 2 | 44 |
| Drotrecogin alfa activated (Xigris) | Eli Lilly | Phase 2 | 52 |
| LY3819469 | Eli Lilly | Phase 1 | 33 |
| Atezolizumab + Cabozantinib | Chugai Pharmaceutical | Phase 3 | 77 |
| DS-6000a + DS-6000a | Daiichi Sankyo | Phase 1 | 33 |
| DS-1093a | Daiichi Sankyo | Phase 1 | 33 |
| CS-3150 | Daiichi Sankyo | Phase 3 | 77 |
| AGS-16C3F | Astellas Pharma | Phase 1 | 33 |
| AGS-16M8F | Astellas Pharma | Phase 1 | 33 |
| CP-461 | Astellas Pharma | Phase 2 | 52 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| YM178 | Astellas Pharma | Phase 1 | 33 |
| intravenous immunoglobulins (IVIG) | Astellas Pharma | Phase 1 | 33 |
| bixalomer | Astellas Pharma | Pre-clinical | 23 |